Abcam, ab250733, Anti-TPGS1 antibody [EPR14324] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal TPGS1 antibody. Carrier free. Suitable for IP, WB, Flow Cyt (Intra) and reacts with Human, Rat, Mouse samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR14324,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:IP, Flow Cyt (Intra), WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250733 is the carrier-free version of
ab184178
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TPGS1 also known as TPR Glycosylation Sensor 1 functions primarily as a sensor and regulator of glycosylation within the cell. Its molecular mass is approximately 85 kDa and it predominantly localizes in the endoplasmic reticulum membrane where it plays an important role in monitoring N-linked glycosylation processes. TPGS1 is expressed in various tissues showing higher levels in organs like the liver and pancreas which are integral to metabolism and detoxification processes.
Biological function summary
The TPGS1 protein interacts with glycoproteins to ensure correct folding and function important for maintaining cellular homeostasis. It frequently operates in association with complexes involved in protein processing particularly those related to the calnexin/calreticulin cycle. TPGS1 contributes to quality control by detecting improperly glycosylated proteins directing them for degradation to prevent accumulation of defective proteins which could disrupt cellular function.
Pathways
TPGS1 plays important roles in the unfolded protein response (UPR) and the endoplasmic reticulum-associated degradation (ERAD) pathways. Within these pathways TPGS1 works closely with proteins such as BiP/GRP78 and EDEM which facilitate the identification and disposal of misfolded glycoproteins. By modulating protein folding and degradation TPGS1 helps maintain ER function and prevent stress conditions that could affect the entire cellular network.
TPGS1 has connections with neurodegenerative diseases and congenital disorders of glycosylation. Mismanagement of glycoproteins due to TPGS1 malfunction can contribute to neurodegenerative conditions where protein aggregation becomes problematic. In congenital glycosylation disorders TPGS1’s interaction with proteins like TMEM165 may lead to incorrect glycosylation patterns resulting in varied systemic symptoms. Understanding TPGS1’s role in these pathological conditions may aid in developing potential therapeutic strategies.